As a result, although several EZH2 inhibitors (EZH2i) have been developed as therapeutic candidates for cancer and a highly specific EZH2i EPZ-6438 (tazemetostat) was approved by the FDA in 2020 as a standalone treatment for epithelioid sarcoma (21), such use of EZH2i for treating solid tumors has not been widely accepted (11). The gene discussed is EZH2; the disease is cancer.